ITEK Insider Trading Activity and SEC Form 4 Filings
ITEK insider trading summary
No open-market insider purchases or sales of Inotek Pharmaceuticals Corp (ITEK) have been reported on SEC Form 4 in the past 12 months.
Latest ITEK insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 6, 2017 | David P Southwell | President and CEO | Buy | $105K (60,000 @ $1.75) |
| May 13, 2016 | J Martin Carroll | Director | Buy | $90K (10,000 @ $9.03) |
| Feb 23, 2015 | Rho Ventures IV Gmbh & Co Beteiligungs Kg | 10% Owner | Buy | $5.7M (958,226 @ $6.00) |
| Feb 23, 2015 | Rho Ventures IV LP | 10% Owner | Buy | $5.7M (958,226 @ $6.00) |
| Feb 23, 2015 | Rho Ventures IV-A, L.P. | 10% Owner | Buy | $5.7M (958,226 @ $6.00) |
| Feb 23, 2015 | Rho Management Ventures IV LLC | 10% Owner | Buy | $5.7M (958,226 @ $6.00) |
| Feb 23, 2015 | Habib Kairouz | 10% Owner | Buy | $5.7M (958,226 @ $6.00) |
| Feb 23, 2015 | Rho Capital Partners Verwaltungs Gmbh | 10% Owner | Buy | $5.7M (958,226 @ $6.00) |
| Feb 23, 2015 | Joshua Ruch | 10% Owner | Buy | $5.7M (958,226 @ $6.00) |
| Feb 23, 2015 | Rho Ventures IV Holdings LLC | 10% Owner | Buy | $5.7M (958,226 @ $6.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.